BioStock: CAR T deal puts spotlight on Elicera’s technology
Is the hype around CAR T-cell therapies real? A recent licensing agreement struck between Legend Biotech and Novartis to advance novel CAR T candidates suggests it might be. The deal raises commercial hopes for other players in the CAR T space, including Swedish biotech Elicera Therapeutics. We asked Elicera’s CEO Jamal El-Mosleh whether Elicera could be bound for a similar deal.Read the interview with Jamal El-Mosleh at biostock.se: CAR T deal puts spotlight on Elicera’s technology - BioStock This is a